These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 10535273)
21. Iron accumulation in chronic hepatitis C: relation of hepatic iron distribution, HFE genotype, and disease course. Corengia C; Galimberti S; Bovo G; Vergani A; Arosio C; Mariani R; Redaelli A; Riva A; Cestari C; Pozzi M; Valsecchi MG; Piperno A Am J Clin Pathol; 2005 Dec; 124(6):846-53. PubMed ID: 16416733 [TBL] [Abstract][Full Text] [Related]
22. The H63D mutation of the hemochromatosis gene is associated with sustained virological response in chronic hepatitis C patients treated with interferon-based therapy: a meta-analysis. Li SH; Zhao H; Ren YY; Liu YZ; Song G; Ding P; Ding YP; Wang GQ Tohoku J Exp Med; 2012 Apr; 226(4):293-9. PubMed ID: 22499121 [TBL] [Abstract][Full Text] [Related]
23. Role of hemochromatosis genes in chronic hepatitis C. Gattoni A; Parlato A; Vangieri B; Bresciani M; Derna R; Baldassarre R Clin Ter; 2006; 157(1):61-8. PubMed ID: 16669553 [TBL] [Abstract][Full Text] [Related]
24. Iron, the HFE gene, and hepatitis C. Eisenbach C; Gehrke SG; Stremmel W Clin Liver Dis; 2004 Nov; 8(4):775-85, vii-viii. PubMed ID: 15464655 [TBL] [Abstract][Full Text] [Related]
25. Effects of iron and HFE mutations on response to therapy in chronic hepatitis C: an ironic interaction? Alexander J; Kowdley KV Gastroenterology; 2006 Nov; 131(5):1635-8. PubMed ID: 17067603 [No Abstract] [Full Text] [Related]
26. Common heterozygous hemochromatosis gene mutations are risk factors for inflammation and fibrosis in chronic hepatitis C. Geier A; Reugels M; Weiskirchen R; Wasmuth HE; Dietrich CG; Siewert E; Gartung C; Lorenzen J; Bosserhoff AK; Brügmann M; Gressner AM; Matern S; Lammert F Liver Int; 2004 Aug; 24(4):285-94. PubMed ID: 15287851 [TBL] [Abstract][Full Text] [Related]
27. A study of some hepatic immunological markers, iron load and virus genotype in chronic hepatitis C. Cardoso EM; Duarte MA; Ribeiro E; Rodrigues P; Hultcrantz R; Sampaio P; Ehrlich R; Carvalho J; Fraga J; de Sousa M J Hepatol; 2004 Aug; 41(2):319-26. PubMed ID: 15288483 [TBL] [Abstract][Full Text] [Related]
28. Non-transferrin-bound iron in untreated and ribavirin-treated chronic hepatitis C patients. Van Vlierberghe H; Verdievel H; Colle I; Delanghe J; Praet M; Bernard D; Leroux-Roels G; De Vos M Aliment Pharmacol Ther; 2002 Aug; 16(8):1555-62. PubMed ID: 12182756 [TBL] [Abstract][Full Text] [Related]
30. Hemochromatosis and transferrin receptor gene polymorphisms in chronic hepatitis C: impact on iron status, liver injury and HCV genotype. Gehrke SG; Stremmel W; Mathes I; Riedel HD; Bents K; Kallinowski B J Mol Med (Berl); 2003 Dec; 81(12):780-7. PubMed ID: 14557859 [TBL] [Abstract][Full Text] [Related]
31. Hepatic iron overload: direct HFE (HLA-H) mutation analysis vs quantitative iron assays for the diagnosis of hereditary hemochromatosis. Press RD; Flora K; Gross C; Rabkin JM; Corless CL Am J Clin Pathol; 1998 May; 109(5):577-84. PubMed ID: 9576576 [TBL] [Abstract][Full Text] [Related]
32. Clinical impact of HFE mutations in Japanese patients with chronic hepatitis C. Ishizu Y; Katano Y; Honda T; Hayashi K; Ishigami M; Itoh A; Hirooka Y; Nakano I; Goto H J Gastroenterol Hepatol; 2012 Jun; 27(6):1112-6. PubMed ID: 22098610 [TBL] [Abstract][Full Text] [Related]
33. Iron as a co-morbid factor in nonhemochromatotic liver disease. Bonkovsky HL; Lambrecht RW; Shan Y Alcohol; 2003 Jun; 30(2):137-44. PubMed ID: 12957298 [TBL] [Abstract][Full Text] [Related]
34. Are haemochromatosis mutations related to the severity of liver disease in hepatitis C virus infection? Martinelli AL; Franco RF; Villanova MG; Figueiredo JF; Secaf M; Tavella MH; Ramalho LN; Zucoloto S; Zago MA Acta Haematol; 2000; 102(3):152-6. PubMed ID: 10692680 [TBL] [Abstract][Full Text] [Related]
35. Porphyria cutanea tarda as a complication of therapy for chronic hepatitis C. Azim J; McCurdy H; Moseley RH World J Gastroenterol; 2008 Oct; 14(38):5913-5. PubMed ID: 18855993 [TBL] [Abstract][Full Text] [Related]
36. [Hemosiderosis in Chronic Hepatitis C: Should Venesection Precede Treatment with Interferon-alpha and Ribavirin?]. Bauditz J; Roske AE; Schmidt HH Z Gastroenterol; 2004 Feb; 42(2):167-70. PubMed ID: 14963790 [No Abstract] [Full Text] [Related]
37. Mutations in the HFE gene and their interaction with exogenous risk factors in hepatocellular carcinoma. Fargion S; Stazi MA; Fracanzani AL; Mattioli M; Sampietro M; Tavazzi D; Bertelli C; Patriarca V; Mariani C; Fiorelli G Blood Cells Mol Dis; 2001; 27(2):505-11. PubMed ID: 11500061 [TBL] [Abstract][Full Text] [Related]
38. Re: Brunt et. al.--Histological evaluation of iron in liver biopsies: relationship to HFE mutations. Mattman A; Huntsman D; Lockitch G; Owen D Am J Gastroenterol; 2001 Mar; 96(3):926. PubMed ID: 11280588 [No Abstract] [Full Text] [Related]
39. HFE mutation analysis in patients with hepatitis C virus with positive screening for iron overload. Remacha AF; Carrasco M; Sardá MP; Barceló MJ; Baiget M Haematologica; 1999 Mar; 84(3):284-5. PubMed ID: 10189401 [No Abstract] [Full Text] [Related]
40. HFE gene mutations in alcoholic and virus-related cirrhotic patients with hepatocellular carcinoma. Lauret E; Rodríguez M; González S; Linares A; López-Vázquez A; Martínez-Borra J; Rodrigo L; López-Larrea C Am J Gastroenterol; 2002 Apr; 97(4):1016-21. PubMed ID: 12003382 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]